Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, publishes the report for the second quarter 2022.

“CHMPs recommendation to grant Pepaxti a full marketing authorization approval in EU is foundational for Oncopeptides says Jakob Lindberg, CEO of Oncopeptides. “This is excellent news for patients, shareholders, and for the future development of Oncopeptides.”

Financial overview April-June

• Net sales amounted to SEK 8.8 M (66.4)
• Operating profit was SEK -61.1 M (-344.8)
• Net profit amounted to SEK -59.8 M (-24.1)
• Profit per share, before and after dilution, amounted to SEK -0.79 (-0.32)
• Cash balances at the end of the period amounted to SEK 90.8M (999.4)

Financial overview January-June

• Net sales amounted to SEK 8.8 M (85.7)
• Operating profit was SEK -160.0 M (-692.2)
• Net profit amounted to SEK -158.4 M (-258.8)
• Profit per share, before and after dilution, amounted to SEK -2.10 (-3.63)
• Cash balances at the end of the period amounted to SEK 90.8M (999.4)

Significant events April-June 

• CHMP, the European Medicines Agency´s Committee for Medicinal Products for Human Use, unanimously recommended the European Commission to grant a full marketing authorization approval of Pepaxti in the EU

Events after the period

• Direct share issue raising approximately SEK 435.6 million (USD 41.1 million) before transaction costs
• FDA has announced an ODAC, a public meeting with the Oncologic Drugs Advisory Committee, on September 22, to discuss benefit/risk of Pepaxto